Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

[PR Newswire] – THOUSAND OAKS, Calif. and DUBLIN, July 21, 2016 /PRNewswire/ — Amgen (AMGN) and Allergan plc (AGN) today announced results from a Phase 3 study evaluating efficacy and safety of ABP 980 compared with trastuzumab in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer. The results ruled out inferiority compared to trastuzumab but could not rule out superiority based on its primary efficacy endpoint of the difference of the percentage of patients with a pathologic complete response (pCR). Overall, adverse events were comparable between ABP 980 and trastuzumab. Read more on this. , valued at $ecting to http://finance.ya, ended session yesterday at $. Looking at today’s market, AMGN one day range is $ with its 52-week range being $. AMGN shares are currently priced at x this year’s forecasted earnings, which makes them relatively inexpensive compared to the industry’s x forward p/e ratio. According to a consensus of 0 analysts, the earnings estimate of $ per share would be $0.00 worse than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $, which would be a $0.00 better than last year. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $0.00 . If realized, that would be a 0.00% decrease over the year-ago quarter. In terms of ratings, d AMGN from to (/fin). Previously, d AMGN from to . The average price target for AMGN shares by the analysts covering the stock is $, which is 0.00% below where the stock opened this morning. See more in (NASDAQ:AMGN) Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen To Participate In The 2016 World Medical Innovation Forum™ On Cancer Stock Update: Amgen Inc (NASDAQ:AMGN) – UK cost agency rejects Amgen’s virus-based cancer drug Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol